9/21/2023 | HY | New Issue: Cheplapharm prices €300 million tap of 7½% notes due 2030 at 100.5 to yield 7.4%
|
9/18/2023 | HY | Cheplapharm sets talk in €300 million two-part add-on to notes
|
9/18/2023 | HY | Cheplapharm announces add-on offerings to 7½%, floaters due 2030
|
4/26/2023 | HY | New Issue: Cheplapharm sells €750 million seven-year secured notes in two parts
|
4/26/2023 | HY | Cheplapharm sets tranche sizes, launches €750 million two-part notes offering; pricing Wednesday
|
4/25/2023 | BKHY | Moody’s assigns B2 to Cheplapharm notes
|
4/25/2023 | HY | Cheplapharm sets initial price talk in €750 million two-part secured notes offering
|
4/24/2023 | BKCVDDEMIGPV | Market Commentary: Tekni-Plex starts roadshow; Kedrion/Kevlar under pressure; Allwyn at premium
|
4/24/2023 | HY | Market Commentary: Tekni-Plex starts roadshow; Kedrion/Kevlar under pressure; Allwyn at a premium; SiriusXM active
|
4/24/2023 | HY | Cheplapharm offers €750 million of secured notes in two parts
|
11/4/2022 | BKHY | S&P ups Cheplapharm
|
2/7/2022 | BKHY | Moody's assigns Cheplapharm loan B2
|
2/7/2022 | BKHY | Fitch rates Cheplapharm loan BB-
|
1/18/2022 | BKHY | Fitch puts Cheplapharm on positive watch
|
1/18/2022 | BKHY | S&P puts Cheplapharm on positive watch
|
12/20/2021 | BKHY | Moody's turns Cheplapharm view to stable
|
10/8/2020 | HY | New Issue: Cheplapharm prices €1 billion equivalent secured notes in two parts
|
10/7/2020 | BKHY | Moody’s alters Cheplapharm view to negative
|
10/7/2020 | HY | Cheplapharm expected to price €1 billion equivalent 7.25-year secured notes on Wednesday
|
10/6/2020 | BKHY | Moody’s rates Cheplapharm notes B2
|
10/5/2020 | BKHY | S&P gives Cheplapharm notes B
|
1/28/2020 | HY | Cheplapharm talks €400 million secured notes due 2027 at 3½%-3¾%
|
1/24/2020 | BK | Moody's rates Cheplapharm loan, notes B2
|
1/24/2020 | BKHY | S&P assigns Cheplapharm loan, notes B
|
1/24/2020 | BKHY | S&P assigns Cheplapharm loan, notes B
|
1/23/2020 | BKHY | Fitch rates Cheplapharm notes BB-
|
10/7/2019 | BK | Moody’s cuts Cheplapharm, view to stable
|
6/10/2019 | BK | Market Commentary: Nuvei Technologies sets talk; Electronics for Imaging kicks off $1.1 billion two-part deal
|
6/10/2019 | BK | Cheplapharm cuts discount on €980 million term B-3, accelerates timing
|
6/5/2019 | BK | Fitch rates Cheplapharm loans BB-
|
5/29/2019 | BK | Cheplapharm launches €980 million term B-3 at Euribor plus 400 bps
|
5/28/2019 | BK | Moody's rates Cheplapharm loan B1, negative view
|
5/28/2019 | BK | Cheplapharm to launch €980 million term loan B-3 on Wednesday
|
11/16/2018 | BK | Cheplapharm finalizes €300 million add-on term B-2 at par issue price
|
11/7/2018 | BK | Cheplapharm shops €300 million add-on term loan B-2 at 99.75-par OID
|
11/6/2018 | BK | S&P rates Cheplapharm Arzneimittel loan B
|
11/6/2018 | BK | Moody's rates Chelapharm loan B1
|
11/2/2018 | BK | Cheplapharm to launch €300 million add-on term loan B-2 on Tuesday
|
8/10/2018 | BK | S&P gives Cheplapharm, loan B
|
6/28/2018 | BK | Cheplapharm flexes term B-1 to Euribor plus 450 bps, drops B-2 plans
|
6/7/2018 | BK | Moody’s rates Cheplapharm, loans B1
|
6/7/2018 | BK | S&P rates Cheplapharm loans B
|